AstraZeneca (AZN) stock is in focus as the company's experimental drug gefurulimab for generalized myasthenia gravis hits Phase 3 trial goals. Read more here.

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG.

Two potential new treatments for a rare condition have been rejected for use on the NHS in England, which has prompted the writing of a joint letter by representatives of two charities. Andy ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...

Alligator Alcatraz, the migrant detention center in the Florida Everglades, is surrounded by swamps infested with massive Burmese pythons.

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL trial and promised to share more at an upcoming scientific meeting.

In the editorial, published in June and titled “Myasthenia Gravis — Redemption for B-Cell Depletion,” Wolfe reevaluates previous research and clinical trials on B-cell depletion and details the more ...